Beyond Thinking

Welcome to Beyond Blue’s Thought Leadership Hub, where we highlight complex concepts with clarity and showcase our commitment to delivering excellence with ease. Explore our insights, discover innovative perspectives and join us on a journey to navigate the intricate with confidence.

ESMO 2025: Ones to watch

ESMO 2025: Ones to watch

Explore the headlines set to surface at ESMO 2025. ADCs make their move into early-stage disease Drugs like Enhertu and Padcev, already headline-makers in metastatic disease, are now making waves in early-stage settings. DESTINY-Breast05, DESTINY-Breast11, and...

Spotlight on BTK Inhibitors in MS

Spotlight on BTK Inhibitors in MS

In recent years, interest in BTK inhibitors (BTKi) for MS has surged, with hopes that they could offer a new way to tackle the underlying drivers of the disease. But the journey, so far, has been a rollercoaster, and the delayed FDA decision on tolebrutinib marks the...

The Power of Words: In sickness and in health

The Power of Words: In sickness and in health

Author: Sam Hope, CEO, Beyond Blue Why is it that some people will happily stick to collagen powders and herbal elixirs but skip life-saving medication? This puzzling question became the spark for our self-funded study. Watching my own mother consistently and...

Data Dump to Strategic Clarity: Make patient chart audits work for you

Data Dump to Strategic Clarity: Make patient chart audits work for you

When you're sitting on hundreds, sometimes thousands, of patient records, the challenge isn’t just collecting the data, or even analysing it. It’s making it usable. Beyond Blue helps you turn complex chart audit data into clear, actionable insight. No more 300-slide...

ASCO 2025: Key market shifts and strategic considerations

ASCO 2025: Key market shifts and strategic considerations

ADCs step into first-line mBC ASCO 2025 highlighted the growing role of ADCs in reshaping metastatic breast cancer treatment. Two key trials, DESTINY-Breast09 and ASCENT-04, showed strong efficacy for ADCs in 1L HER2+ mBC and PD-L1+ TNBC respectively, raising the...